Feedback
Settings

Settings

Goto Application

1. WO2022094721 - SARS-COV-2 CONSTRUCTS, VACCINES, AND METHODS

Submit observation
PermaLink
Publication Number WO/2022/094721
Publication Date 12.05.2022
International Application No. PCT/CA2021/051581
International Filing Date 05.11.2021
IPC
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61K 39/385 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
385Haptens or antigens, bound to carriers
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • THE HOSPITAL FOR SICK CHILDREN [CA]/[CA]
Inventors
  • JULIEN, Jean-Philippe
  • KASSARDJIAN, Audrey
  • BARBER, Brian
Agents
  • LOWTHERS, Erica L.
  • MCMANUS, Kimberly A.
  • SINDEN, William K.
  • REECE, Pia-Lauren
  • BARTOSZEWICZ, Lola A.
  • SABETA, Anton C.
  • HUNDAL, Steve S.
  • MILLMAN, Jay M.
Priority Data
63/110,88106.11.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SARS-COV-2 CONSTRUCTS, VACCINES, AND METHODS
(FR) CONSTRUCTIONS, VACCINS ET MÉTHODES CONTRE LE SARS-COV-2
front page image
Abstract
(EN) Described herein is an anti-class II MHC antibody fused to a SARS-CoV-2 antigen. Also described is a vaccine comprising the antibody and methods for treating and/or preventing SARS-CoV-2, wherein the methods comprise administering the antibody to a subject in need thereof. In typical aspects, the vaccine is free of an adjuvant.
(FR) L'invention concerne un anticorps anti CMH de classe II fusionné à un antigène du SARS-CoV-2. L'invention concerne également un vaccin comprenant l'anticorps et des méthodes de traitement et/ou de prévention du SARS-CoV-2, les méthodes comprenant l'administration de l'anticorps à un sujet en ayant besoin. Dans des aspects typiques, le vaccin est exempt d'un adjuvant.
Latest bibliographic data on file with the International Bureau
# -